Published in Vaccine Weekly, November 21st, 2001
Therion will use the funds to support clinical trials of PROSTVAC-VF, the company's lead cancer vaccine for prostate cancer, and to accelerate the development of its additional therapeutic cancer vaccine programs.
The financing was led by a group including Hans-Werner Hector, one of the founders of the German software company SAP. In addition to Hector's investment in Therion, he has established one of the largest private charitable foundations in Germany, through which he...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly